Found 12 matching trials
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02) PHASE1 Subjects will be adults aged 50 to 85 years who have subjective memory comp...
Show More Location
Multiple Locations
Learn More & Join Trial
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease PHASE2 This is a Phase 2 study to evaluate safety and efficacy in participants wit...
Show More Location
Multiple Locations
Learn More & Join Trial
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort PHASE1 The purpose of this study is to evaluate the safety, tolerability, pharmaco...
Show More Location
Glendale Adventist Medical Center
Learn More & Join Trial
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects PHASE1 This study is primarily designed to bridge the pharmacokinetics (PK) and sa...
Show More Location
Multiple Locations
Learn More & Join Trial
An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption PHASE1 This study will be a single-center, open-label, randomized, 3-treatment cro...
Show More Location
California Clinical Trials/Parexel
Learn More & Join Trial
A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil PHASE1 This study will be a single-center, open-label, drug-drug interaction study...
Show More Location
WCT Early Development
Learn More & Join Trial
Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects PHASE1 Study E2609-J081-014 is a single-center, randomized, double-blind, placebo-...
Show More Learn More & Join Trial
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects PHASE1 The primary objective of the study is to evaluate the effects of hepatic im...
Show More Location
Multiple Locations
Learn More & Join Trial
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease PHASE3 The name of this trial is MissionAD1. This phase 3 study consists of a Core...
Show More Learn More & Join Trial
A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects PHASE1 This thorough QT (TQT) study will take place in healthy subjects administer...
Show More Location
Multiple Locations
Learn More & Join Trial